Exploiting Mutant IDH1/2-induced DNA Repair Defects in Pediatric Glioma to improve outcomes

Head/Neck Cancer
Rizwan Romee, MD
Dana-Farber Cancer Institute


This clinical trial is examining the novel use of manufactured, personalized cytokine-induced, memory-like natural killer cells (CIML NK cells) to improve immune response against squamous cell carcinoma of the head and neck (SCCHN) tumor cells, thus improving the effectiveness of the immunotherapy drug (ipilimumab). Patients will first receive ipilimumab, then they will undergo a round of chemotherapy (fludarabine and cyclophosphamide), finally the patient will receive the CIML NK cells with a special IL-15 protein to promote their lifespan and activity. If successful, this protocol will be a needed advancement in the treatment of advanced SCCNH cancer patients.

Trial Registration: ClinicalTrials.gov Identifier: NCT04290546